Patents Assigned to OSI Pharmaceuticals, Inc.
-
Patent number: 7645754Abstract: The subject invention provides compounds having the structure: wherein, R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(?O)NRaRb, —NRaRb, —NRaC(?O)NRaRb, —NRaC(?O)ORa, —OC(?O)NRaRb, or —NHC(?O) Ra; R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(?O)NRaRb, —NRaRb, —NRaC(?O)NRaRb, —NRaC(?O)ORa, —OC(?O)NRaRb, or —NHC(?O)Ra, or R1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(?O)OH; R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb; R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl; R5 is —(CH2)mOR6, —CHNOR7, —C(?O)NR8R9, —(CH2)mC(?O)OR10, —(CH2)kC(?O)NR11R12; wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroarylType: GrantFiled: June 19, 2007Date of Patent: January 12, 2010Assignee: OSI Pharmaceuticals, Inc.Inventors: Arlindo Castelhano, Bryan McKibben, Arno Steinig
-
Publication number: 20090286768Abstract: Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention.Type: ApplicationFiled: May 19, 2009Publication date: November 19, 2009Applicant: OSI Pharmaceuticals, Inc.Inventors: Andrew P. Crew, Meizhong Jin, Mridula Kadalbajoo, Andrew Kleinberg, Mark J. Mulvihill, Jing Wang
-
Patent number: 7618965Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, R1, R2, and R5 are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.Type: GrantFiled: September 15, 2005Date of Patent: November 17, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Andrew Crew, An-Hu Li, Bijoy Panicker
-
Patent number: 7608577Abstract: The present invention relates to compounds of the general formula 1 and pharmaceutically acceptable salts thereof, to the use of the compounds for the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidosis, diabetes mellitus, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus in mammals.Type: GrantFiled: August 9, 2002Date of Patent: October 27, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Ulrich Heiser, André Johannes Niestroj, Torsten Hoffmann, Hans-Ulrich Demuth
-
Patent number: 7598252Abstract: This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.Type: GrantFiled: November 20, 2003Date of Patent: October 6, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
-
Patent number: 7566721Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.Type: GrantFiled: August 3, 2006Date of Patent: July 28, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Qun-Sheng Ji, Mark Joseph Mulvihill, Arno G. Steinig, Qinghua Weng
-
Patent number: 7534797Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.Type: GrantFiled: March 31, 2005Date of Patent: May 19, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Lee D. Arnold, Mark Joseph Mulvihill
-
Patent number: 7524859Abstract: A method of treatment of hyperproliferative disorders comprises a step of administering an effective amount of a compound represented byType: GrantFiled: June 28, 2006Date of Patent: April 28, 2009Assignee: OSI Pharmaceuticals, Inc.Inventor: Andrew Phillip Crew
-
Patent number: 7524638Abstract: This invention relates to the identification of LPA as a ligand for the G-protein coupled receptors OSGPR114 and OSGPR78. The invention is directed to new methods for screening candidate drugs for their ability to modulate the activity of OSGPR114 or OSGPR78, and new pharmaceutical agents identified by these methods. It is also directed to the use of such agents in the manufacture of medicaments for the treatment of OSGPR114 or OSGPR78 mediated diseases, and methods of treating diseases such as cancers by administering to an individual a therapeutic amount of a modulator of OSGPR114 or OSGPR78 identified by these methods.Type: GrantFiled: June 25, 2004Date of Patent: April 28, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Graeme Griffin, Lambertus J. Oehlen
-
Patent number: 7521456Abstract: The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.Type: GrantFiled: November 17, 2003Date of Patent: April 21, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Douglas John Meldrum Allen, Timothy Norris, Jeffrey William Raggon, Dinos Paul Santafianos, Ravi Mysore Shanker
-
Patent number: 7521448Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.Type: GrantFiled: August 16, 2004Date of Patent: April 21, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Joshua Bolger, Arlindo L. Castelhano, Andrew Phillip Crew, Han-Qing Dong, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Mulvihill, Li Qiu, Colin Peter Sambrook Smith, Yingchaun Sun, Graham Michael Wynne, Tao Zhang
-
Patent number: 7504407Abstract: This invention pertains to compounds having the structure: wherein m is 0, 1, 2, or 3; R2 is a substituted or unsubstituted imidazole or pyrazole wherein the point of attachment of R2 to the alkyl chain is not N; R5 is a hydrogen atom or a substituted or unsubstituted alkyl, aryl, or alkylaryl moiety; and R7 is a halogen atom, C1-C4 alkyl, OH, O-alkyl(C1-C4), NH2, or NH-alkyl(C1-C4), which specifically inhibit the adenosine A1 and A3 receptors and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compound.Type: GrantFiled: November 27, 2002Date of Patent: March 17, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Arlindo L. Castelhano, Bryan McKibben, Douglas S. Werner, David Witter
-
Patent number: 7501407Abstract: The subject invention provides compounds having the structure: wherein R1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R2 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety; R3 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R2 and R3 are joined to form a heterocyclic ring; wherein the dashed line represents a second bond which may be present or absent, and when present R3 is oxygen; R4 and R5 are each independently substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R4NR5 together form a substituted or unsubstituted monocyclic or bicyclic, heterocyclic or heteroaryl mType: GrantFiled: November 18, 2004Date of Patent: March 10, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Arlindo Castelhano, Bryan McKibben, Arno Steinig, Eric Collington
-
Patent number: 7498354Abstract: or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of tumors and cancers.Type: GrantFiled: March 30, 2006Date of Patent: March 3, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Andrew Philip Crew, Bijoy Panicker, Han-Qing Dong
-
Patent number: 7485658Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.Type: GrantFiled: August 16, 2004Date of Patent: February 3, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Joshua Bolger, Arlindo L. Castelhano, Andrew Phillip Crew, Radoslaw Laufer, An-Hu Li, Colin Peter Sambrook Smith, Yingchuan Sun
-
Patent number: 7465726Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.Type: GrantFiled: August 1, 2005Date of Patent: December 16, 2008Assignee: OSI Pharmaceuticals, Inc.Inventors: Saleh Ahmed, Oscar Barba, Jason Bloxham, Graham Dawson, William Gattrell, John Kitchin, Neil Anthony Pegg, Imaad Saba, Shazia Sadiq, Colin Peter Sambrook Smith, Don Smyth, Amo G. Steinig, Robin Wilkes, Bijoy Panicker, Paula Tavares, Matthew Cox, An-Hu Li, Hanqing Dong, Lifu Ma, Kenneth (‘Ken’) Foreman, Qinghua (‘Felix’) Weng, Kathryn Stolz
-
Publication number: 20080300249Abstract: The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.Type: ApplicationFiled: July 29, 2008Publication date: December 4, 2008Applicants: PFIZER, INC., OSI PHARMACEUTICALS, INC.Inventors: Eric R. Larson, Mark C. Noe, Thomas G. Gant
-
Patent number: 7459554Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.Type: GrantFiled: October 14, 2004Date of Patent: December 2, 2008Assignee: OSI Pharmaceuticals, Inc.Inventors: Han-Qing Dong, Kenneth Foreman, Mark Joseph Mulvihill, Anthony Innocenzo Nigro, Arno G. Steinig, Douglas Werner, Robin Wilkes
-
Patent number: 7442709Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.Type: GrantFiled: August 16, 2004Date of Patent: October 28, 2008Assignee: OSI Pharmaceuticals, Inc.Inventors: Arlindo L. Castelhano, Andrew Phillip Crew, Han-Qing Dong, Radoslaw Laufer, An-Hu Li, Li Qiu, Colin Peter Sambrook Smith, Tao Zhang
-
Patent number: RE41065Abstract: The invention relates to compounds of the formula and to pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as cancer. The invention further relates to processes of making the compounds of formula I and to methods of using such compounds in the treatment of hyperproliferative diseases.Type: GrantFiled: February 27, 2008Date of Patent: December 29, 2009Assignees: Pfizer, Inc., OSI Pharmaceuticals, Inc.Inventors: Rodney Caughren Schnur, Lee Daniel Arnold